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Pineda and colleagues [1] published a well-performed meta-
analysis of four randomized controlled trials (RCTs) [2-5]
exploring the effect of oral chlorhexidine (CHX) application on
the incidence of nosocomial pneumonia (NP) in mechanically
ventilated patients. They concluded that oral CHX decontamina-
tion did not reduce the incidence of NP in such patients;
however, they clearly stated that the combined sample size of
the four RCTs included may be inadequate for detecting
important differences. Meanwhile, additional important data
on this issue have been published; updating the findings of
the above meta-analysis [1] is therefore warranted.
In detail, Koeman and colleagues [6] enrolled intensive care
unit patients requiring mechanical ventilation in a large,
multicenter, double-blind, three-arm RCT. Ventilator-associated
pneumonia developed in 13 out of 127 (10%) patients treated
with 2% CHX paste, in 16 out of 128 (13%) subjects treated
with 2% CHX and 2% colistin paste, and in 23 out of 130
(18%) placebo recipients. One additional RCT (in fact, a pilot
study) conducted by Bopp and colleagues [7] in patients
intubated in the intensive care unit reported that neither of two
(0%) patients treated with 0.12% CHX gluconate and one out
of three (33%) patients who received standard oral care (with
soft foam swab and hydrogen peroxide) developed NP.
We used data from the four RCTs [2-5] included in the meta-
analysis by Pineda and colleagues [1] as well as data from
the two RCTs published later [6,7] to estimate the pooled
odds ratio (OR) and 95% confidence intervals (CIs) for the
incidence of NP. Both the Mantel–Haenszel fixed-effect
model and the DerSimonian–Laird random effects model
were employed. Heterogeneity between RCTs was assessed
using both a chi-square test and the I2 statistic. Statistical
analyses were performed using the ‘S-PLUS 6.1’ software.
Oral application with CHX in mechanically ventilated
patients was associated with reduced incidence of NP
compared with control individuals (fixed-effect model, OR =
0.55, 95% CI = 0.36–0.84; random effects model, OR =
0.56, 95% CI = 0.36–0.86; data from six trials [2-7],
Figure 1). No heterogeneity was detected between the trials
(P = 0.48, I2 = 0, 95% CI = 0–0.75). It should be mentioned
that we omitted patients treated with CHX and antibiotic
from our analysis in an attempt to avoid confounding. In
addition, we performed a subgroup analysis by excluding
RCTs conducted in a cardiac surgery population [2,5]. The
rationale for this subanalysis was that cardiac surgery
patients were at lower risk of developing NP than intensive
care unit patients due to the shorter duration of mechanical
ventilation [6]. Using the fixed-effect model, we found that
oral decontamination with CHX was associated with lower
NP incidence in intensive care unit patients compared with
controls (OR = 0.61, 95% CI = 0.37–0.99; data from four
RCTs [3,4,6,7]); however, the statistical significance of this
finding did not remain when a random effects model was
employed (OR = 0.60, 95% CI = 0.33–1.09; Figure 2).
Employment of a fixed-effect model for this analysis seems
reasonable because there was no heterogeneity between
these four RCTs [3,4,6,7] (P = 0.29, I2 = 0.20, 95% CI =
0–0.88).
We believe current evidence suggests that oral decon-
tamination with CHX may reduce the NP incidence in
mechanically ventilated patients. Given its low cost and
safety, CHX may be considered among the preventive
measures for NP. Further investigation is warranted to
confirm these promising findings as well as to evaluate the
potential impact of CHX overuse on induction of antimicrobial
resistance.
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Figure 1
Odds ratios of the incidence of nosocomial pneumonia for the
individual randomized controlled trials comparing chlorhexidine and
controls for the management of mechanically ventilated patients and
the pooled analysis. Vertical line, ‘no difference’ point between the two
regimens; square, odds ratio (size of each square denotes the
proportion of information given by each trial); diamond, pooled odds
ratio for all randomized controlled trials; horizontal lines, 95%
confidence intervals.
Figure 2
Odds ratios of the incidence of nosocomial pneumonia for the
individual randomized controlled trials comparing chlorhexidine and
controls for the management of mechanically ventilated patients in the
intensive care unit setting and the pooled analysis. Vertical line, ‘no
difference’ point between the two regimens; square, odds ratio (size of
each square denotes the proportion of information given by each trial);
diamond, pooled odds ratio for all randomized controlled trials;
horizontal lines, 95% confidence intervals.
Reply from the authors
Lilibeth A Pineda, Brydon JB Grant and Ali A El Solh
We would like to thank Dr Siempos and Dr Falagas for their
comments on our study [1].
In our meta-analysis, we set up a priori to use a random
effects model to account for the between-study variations
with regard to an overall mean of the effects of all the studies
[8]. There were variations among the studies in terms of the
CHX dose, the clinical setting, and the criteria of ventilator-
associated pneumonia. We therefore felt that these variations
should be taken into account despite the fact that we did not
detect any heterogeneity between the selected trials.
Inherent to any meta-analysis, new trials will become available –
warranting an update of the analysis. With the addition of two
recent trials favoring the use of CHX [6,7] the sample size
increased by 21%, yet the results of the subgroup analysis
showed a significant reduction in ventilator-associated
pneumonia only when a fixed-effect model was applied. It is
noteworthy to mention that the study of Bopp and colleagues
[7] was a pilot study that included only five patients. In their
methods, Bopp and colleagues [7] stated that, due to the
small sample size, their investigation was modified to a case
study and they mainly used descriptive statistics.
Finally, we would like to point out that the diagnosis of
ventilator-associated pneumonia in these trials was, in the
majority, based on clinical criteria and endotracheal aspirates
rather than on quantitative cultures of the lower respiratory
tract. Given the limitations of these diagnostic criteria, the
proof of CHX efficacy in reducing the rate of ventilator-
associated pneumonia remains elusive. Nonetheless,
because of the low risk and cost of CHX, we feel that CHX
may be added to the oral care of intubated patients while
awaiting the results of future RCTs.
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